All material subject to strictly enforced copyright laws. © 2021 Euromoney Institutional Investor PLC group
EquityEquity IPOs

Freeline sets range for US IPO as biotech 'bananas' surge continues


Freeline Therapeutics, the UK gene therapeutics company, has set a pricing range for its Nasdaq listing, becoming the latest company from the red hot biotech sector to raise equity capital.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree